Open access · OA
via Europe PMC
Stem cell senescence as a regenerative bottleneck in age-related skeletal degeneration: Mechanistic crosstalk and translational strategies
Wang X, Huang Y, Zhu T, Qiu H.
Regenerative therapy · 2026
Abstract
This Regenerative Therapy 2026 article examines stem cell senescence(definition) as a barrier to skeletal regeneration. It reviews mechanistic crosstalk and strategies.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- Europe PMC
- Canonical
- link ↗
- Fetched
- 2026-10-08 MST
Cite this
APA
X, W., Y, H., T, Z., & H., Q. (2026). Stem cell senescence as a regenerative bottleneck in age-related skeletal degeneration: Mechanistic crosstalk and translational strategies. <em>Regenerative therapy</em>. https://europepmc.org/article/PMC/PMC13636325
Vancouver
X W, Y H, T Z, H. Q. Stem cell senescence as a regenerative bottleneck in age-related skeletal degeneration: Mechanistic crosstalk and translational strategies. Regenerative therapy. 2026.
BibTeX
@article{wang2026Stemce,
title = {Stem cell senescence as a regenerative bottleneck in age-related skeletal degeneration: Mechanistic crosstalk and translational strategies},
author = {Wang X and Huang Y and Zhu T and Qiu H.},
journal = {Regenerative therapy},
year = {2026},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Developmental Biology 2011
Open access · OA
Mdm2–p53 signaling regulates epidermal stem cell senescence and premature aging phenotypes in mouse skin
JAMA 2020
Citation only
Current Perspective on Age-Related Macular Degeneration
Journal of Dermatological Science 2026
Citation only
Collagen XVIIα1 in skin and hair aging: Mechanisms, stem cell niche regulation, and translational strategies
Chinese Academy of Sciences 2018
Open access · US-GOV
Safety and Efficacy of Subretinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigment Epitheliums in Treatment of Age-related Macular Degeneration Diseases
EyebioKorea, Inc. 2024
Open access · US-GOV
A Randomization, Double-blind, Parallel, Multicenter-Phase 2a Trial to Evaluate the Safety and Efficacy of EB-203 in Patients With Neovascular Age-related Macular Degeneration
Cell 2019
Open access · OA